Total Payments
$2,134
2021 Payments
$102.12
Companies
15
Transactions
30
Medicare Patients
1,599
Medicare Billing
$176,843
Payment Breakdown by Category
Food & Beverage$2,036 (95.4%)
Education$97.78 (4.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,036 | 27 | 95.4% |
| Education | $97.78 | 3 | 4.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $307.01 | 3 | $0 (2019) |
| Millennium Pharmaceuticals, Inc. | $276.23 | 3 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $213.04 | 2 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $204.67 | 3 | $0 (2021) |
| Genentech USA, Inc. | $168.23 | 2 | $0 (2018) |
| Janssen Biotech, Inc. | $144.09 | 2 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $125.43 | 7 | $0 (2019) |
| Clovis Oncology, Inc. | $106.83 | 1 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $105.00 | 1 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $100.74 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $102.12 | 2 | Janssen Biotech, Inc. ($82.84) |
| 2020 | $214.14 | 3 | Alexion Pharmaceuticals, Inc. ($94.01) |
| 2019 | $521.92 | 11 | Takeda Pharmaceuticals U.S.A., Inc. ($213.04) |
| 2018 | $563.31 | 6 | Genentech USA, Inc. ($168.23) |
| 2017 | $732.68 | 8 | Millennium Pharmaceuticals, Inc. ($276.23) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: ONCOLOGY | ||||||
| 08/18/2021 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $82.84 | General |
| Category: Oncology | ||||||
| 02/25/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $61.25 | General |
| Category: Oncology | ||||||
| 02/12/2020 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $58.88 | General |
| Category: Oncology | ||||||
| 01/21/2020 | Alexion Pharmaceuticals, Inc. | Ultomiris (Drug) | Food and Beverage | In-kind items and services | $94.01 | General |
| Category: Immunology | ||||||
| 10/29/2019 | E.R. Squibb & Sons, L.L.C. | SPRYCEL (Drug) | Food and Beverage | Cash or cash equivalent | $8.40 | General |
| Category: Oncology | ||||||
| 08/06/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $108.91 | General |
| 07/24/2019 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $104.13 | General |
| Category: Oncology | ||||||
| 06/06/2019 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Education | Cash or cash equivalent | $6.25 | General |
| Category: Oncology | ||||||
| 05/13/2019 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Education | Cash or cash equivalent | $6.33 | General |
| Category: Oncology | ||||||
| 05/13/2019 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $2.86 | General |
| Category: Oncology | ||||||
| 05/09/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $96.47 | General |
| Category: Oncology | ||||||
| 03/26/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $3.00 | General |
| Category: Oncology | ||||||
| 03/26/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $2.12 | General |
| Category: Oncology | ||||||
| 03/05/2019 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $91.23 | General |
| Category: Oncology | ||||||
| 01/29/2019 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $92.22 | General |
| Category: Oncology | ||||||
| 11/01/2018 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $106.83 | General |
| Category: Oncology | ||||||
| 10/16/2018 | GENZYME CORPORATION | LIBTAYO (Drug) | Food and Beverage | In-kind items and services | $89.09 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2018 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $78.92 | General |
| Category: BioOncology | ||||||
| 07/25/2018 | Genentech USA, Inc. | Alecensa (Biological) | Food and Beverage | In-kind items and services | $89.31 | General |
| Category: BioOncology | ||||||
| 05/02/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $94.16 | General |
| Category: Oncology | ||||||
| 01/10/2018 | Janssen Scientific Affairs, LLC | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $105.00 | General |
| Category: Oncology | ||||||
| 11/30/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $66.96 | General |
| Category: Oncology | ||||||
| 10/05/2017 | Millennium Pharmaceuticals, Inc. | VELCADE (Drug) | Education | In-kind items and services | $85.20 | General |
| Category: Oncology | ||||||
| 10/04/2017 | Millennium Pharmaceuticals, Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $97.29 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 105 | 117 | $18,504 | $9,318 |
| 2022 | 3 | 184 | 197 | $45,188 | $7,863 |
| 2021 | 9 | 645 | 1,299 | $280,364 | $86,109 |
| 2020 | 9 | 665 | 1,320 | $277,874 | $73,553 |
Total Patients
1,599
Total Services
2,933
Medicare Billing
$176,843
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 42 | $8,218 | $4,378 | 53.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 49 | $6,949 | $3,439 | 49.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 13 | 13 | $2,154 | $993.59 | 46.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 13 | $1,183 | $506.87 | 42.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 71 | 78 | $21,840 | $3,497 | 16.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 99 | 105 | $19,950 | $2,613 | 13.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 14 | $3,398 | $1,754 | 51.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 254 | 654 | $141,918 | $46,148 | 32.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 66 | 172 | $49,192 | $13,829 | 28.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 188 | 252 | $35,532 | $11,163 | 31.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 43 | 116 | $22,968 | $6,502 | 28.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 37 | 37 | $13,172 | $3,541 | 26.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 16 | 21 | $6,426 | $1,995 | 31.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 14 | 16 | $6,048 | $1,528 | 25.3% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 14 | 16 | $3,488 | $947.25 | 27.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 13 | 15 | $1,620 | $456.90 | 28.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 292 | 747 | $161,705 | $42,448 | 26.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 51 | 125 | $35,685 | $10,009 | 28.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 202 | 249 | $34,985 | $8,147 | 23.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 42 | 106 | $21,034 | $6,012 | 28.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 23 | 23 | $8,170 | $2,389 | 29.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 14 | 16 | $6,027 | $1,688 | 28.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 13 | $3,970 | $1,131 | 28.5% |
| 38222 | Bone marrow biopsy and aspiration | Facility | 2020 | 14 | 17 | $3,706 | $1,026 | 27.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 15 | 24 | $2,592 | $704.15 | 27.2% |
About Dr. Malcolm Winter, M.D
Dr. Malcolm Winter, M.D is a Hematology & Oncology healthcare provider based in Bremerton, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902979404.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Malcolm Winter, M.D has received a total of $2,134 in payments from pharmaceutical and medical device companies, with $102.12 received in 2021. These payments were reported across 30 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($2,036).
As a Medicare-enrolled provider, Winter has provided services to 1,599 Medicare beneficiaries, totaling 2,933 services with total Medicare billing of $176,843. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Bremerton, WA
- Active Since 11/15/2006
- Last Updated 01/18/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1902979404
Products in Payments
- NINLARO (Drug) $201.42
- DARZALEX (Biological) $187.84
- Imbruvica (Drug) $185.39
- Revlimid (Drug) $111.08
- Rubraca (Drug) $106.83
- OPDIVO (Biological) $101.59
- KEYTRUDA (Biological) $100.74
- Ultomiris (Drug) $94.01
- Abraxane (Drug) $92.22
- Alecensa (Biological) $89.31
- LIBTAYO (Drug) $89.09
- VELCADE (Drug) $85.20
- Perjeta (Biological) $78.92
- JAKAFI (Drug) $73.96
- VYXEOS (Drug) $66.96
- ERLEADA (Drug) $61.25
- Kyprolis (Drug) $58.88
- IMBRUVICA (Drug) $19.28
- EMPLICITI (Biological) $15.44
- SPRYCEL (Drug) $8.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.